Literature DB >> 33403050

Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer.

Yiqun Han1, Jiayu Wang1, Binghe Xu1.   

Abstract

Objective: To develop and validate a prediction model for the pathological complete response (pCR) to neoadjuvant chemotherapy (NCT) of triple-negative breast cancer (TNBC).
Methods: We systematically searched Gene Expression Omnibus, ArrayExpress, and PubMed for the gene expression profiles of operable TNBC accessible to NCT. Molecular heterogeneity was detected with hierarchical clustering method, and the biological profiles of differentially expressed genes were investigated by Gene Ontology, Kyoto Encyclopedia of Genes and Genomes analyses, and Gene Set Enrichment Analysis (GSEA). Next, machine-learning algorithms including random-forest analysis and least absolute shrinkage and selection operator (LASSO) analysis were synchronously performed and, then, the intersected proportion of significant genes was undergone binary logistic regression to fulfill variables selection. The predictive response score (pRS) system was built as the product of the gene expression and coefficient obtained from the logistic analysis. Last, the cohorts were randomly divided in a 7:3 ratio into training cohort and validation cohort for the introduction of a robust model, and a nomogram was constructed with the independent predictors for pCR rate.
Results: A total of 217 individuals from four cohort datasets (GSE32646, GSE25065, GSE25055, GSE21974) with complete clinicopathological information were included. Based on the microarray data, a six-gene panel (ATP4B, FBXO22, FCN2, RRP8, SMERK2, TET3) was identified. A robust nomogram, adopting pRS and clinical tumor size stage, was established and the performance was successively validated by calibration curves and receiver operating characteristic curves with the area under curve 0.704 and 0.756, respectively. Results of GSEA revealed that the biological processes including apoptosis, hypoxia, mTORC1 signaling and myogenesis, and oncogenic features of EGFR and RAF were in proactivity to attribute to an inferior response. Conclusions: This study provided a robust prediction model for pCR rate and revealed potential mechanisms of distinct response to NCT in TNBC, which were promising and warranted to further validate in the perspective. © The author(s).

Entities:  

Keywords:  molecular heterogeneity; neoadjuvant chemotherapy; nomogram; pathological complete response; triple-negative breast cancer

Year:  2021        PMID: 33403050      PMCID: PMC7778555          DOI: 10.7150/jca.52439

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  39 in total

1.  Measures of outcome in metastatic breast cancer: insights from a real-world scenario.

Authors:  Marta Bonotto; Lorenzo Gerratana; Elena Poletto; Pamela Driol; Manuela Giangreco; Stefania Russo; Alessandro M Minisini; Claudia Andreetta; Mauro Mansutti; Federica E Pisa; Gianpiero Fasola; Fabio Puglisi
Journal:  Oncologist       Date:  2014-05-02

2.  Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

Authors:  Anne-Sophie Hamy; Hélène Bonsang-Kitzis; Marick Laé; Fabien Reyal; Diane De Croze; Enora Laas; Lauren Darrigues; Lucian Topciu; Emmanuelle Menet; Anne Vincent-Salomon; Florence Lerebours; Jean-Yves Pierga; Etienne Brain; Jean-Guillaume Feron; Gabriel Benchimol; Giang-Thanh Lam
Journal:  Clin Cancer Res       Date:  2019-09-12       Impact factor: 12.531

3.  Regularization Paths for Generalized Linear Models via Coordinate Descent.

Authors:  Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2010       Impact factor: 6.440

4.  Association of caspase 8 promoter variants and haplotypes with the risk of breast cancer and its molecular profile in an Iranian population: A case-control study.

Authors:  Matineh Barati Bagherabad; Fahimeh Afzaljavan; Elham Vahednia; Mahdi Rivandi; Fatemeh Vakili; Susan Sadat Hashemi Sadr; Fatemeh Homaei Shandiz; Alireza Pasdar
Journal:  J Cell Biochem       Date:  2019-06-30       Impact factor: 4.429

5.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

6.  Predictors of Response and Survival Outcomes of Triple Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.

Authors:  Meizhen Zhu; Yang Yu; Xiying Shao; Liang Zhu; Linbo Wang
Journal:  Chemotherapy       Date:  2020-09-07       Impact factor: 2.544

7.  Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.

Authors:  Reva K Basho; Michael Gilcrease; Rashmi K Murthy; Thorunn Helgason; Daniel D Karp; Funda Meric-Bernstam; Kenneth R Hess; Shelley M Herbrich; Vicente Valero; Constance Albarracin; Jennifer K Litton; Mariana Chavez-MacGregor; Nuhad K Ibrahim; James L Murray; Kimberly B Koenig; David Hong; Vivek Subbiah; Razelle Kurzrock; Filip Janku; Stacy L Moulder
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

Review 8.  Triple negative breast cancer: special histological types and emerging therapeutic methods.

Authors:  Lu Cao; Yun Niu
Journal:  Cancer Biol Med       Date:  2020-05-15       Impact factor: 4.248

9.  Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer.

Authors:  J D Kuhlmann; A Bankfalvi; K W Schmid; R Callies; R Kimmig; P Wimberger; W Siffert; H S Bachmann
Journal:  BMC Cancer       Date:  2016-08-09       Impact factor: 4.430

10.  Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer.

Authors:  Chuqian Lei; Ciqiu Yang; Bin Xia; Fei Ji; Yi Zhang; Hongfei Gao; Qianqian Xiong; Yufeng Lin; Xiaosheng Zhuang; Liulu Zhang; Teng Zhu; Minyi Cheng; Mei Yang; Kun Wang
Journal:  J Breast Cancer       Date:  2020-01-22       Impact factor: 3.588

View more
  3 in total

1.  Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.

Authors:  Yanbo Li; Yongzi Chen; Rui Zhao; Yu Ji; Junnan Li; Ying Zhang; Hong Lu
Journal:  Eur Radiol       Date:  2021-11-12       Impact factor: 7.034

2.  Validating RRP12 Expression and Its Prognostic Significance in HCC Based on Data Mining and Bioinformatics Methods.

Authors:  Chao Wei; Ben Wang; Zhong-Huo Chen; Han Xiao; Lei Tang; Jia-Fu Guan; Rong-Fa Yuan; Xin Yu; Zhi-Gang Hu; Hua-Jun Wu; Zhi Dai; Kai Wang
Journal:  Front Oncol       Date:  2022-02-01       Impact factor: 6.244

3.  Knockdown of CDCA5 suppresses malignant progression of breast cancer cells by regulating PDS5A.

Authors:  Yang Wang; Jian Yao; Yulin Zhu; Xuejiao Zhao; Jing Lv; Fulan Sun
Journal:  Mol Med Rep       Date:  2022-05-04       Impact factor: 3.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.